EXPERIENCES WITH JERYL LYNN STRAIN LIVE ATTENUATED MUMPS VIRUS VACCINE IN A PEDIATRIC OUTPATIENT CLINIC
- 1 November 1967
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 40 (5) , 798-803
- https://doi.org/10.1542/peds.40.5.798
Abstract
A controlled study of B level Jeryl Lynn strain live attenuated mumps virus vaccine was carried out during June through November 1966 in the pediatric outpatient clinic of the John F. Kennedy Memorial Hospital in Philadelphia. Altogether, 924 children were given the vaccine and paired sera were taken from a sample of 101 of the children for purpose of measuring initial serologic status for mumps and for ascertaining antibody responses. Based on the results obtained, it was estimated that roughly 410 of the children who were vaccinated were initially seronegative for mumps. Forty-eight of the 49 children sampled who were initially without antibody developed mumps antibody following vaccination, giving a seroconversion rate of 98%. The vaccinated children presented no evidence of fever or other untoward clinical reaction referable to the vaccine. It was concluded that the vaccine was safe, highly efficacious in stimulating the production of neutralizing antibody, and readily applicable to the routine pediatric clinic.This publication has 1 reference indexed in Scilit:
- Live Attenuated Mumps Virus Vaccine. 1. Vaccine DevelopmentExperimental Biology and Medicine, 1966